IRIS
FABBIANI, MASSIMILIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.297
EU - Europa 8.681
AS - Asia 6.337
SA - Sud America 1.294
AF - Africa 497
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 9
Totale 27.133
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.056
IT - Italia 2.359
RU - Federazione Russa 2.217
SG - Singapore 1.894
CN - Cina 1.573
BR - Brasile 1.077
GB - Regno Unito 930
IE - Irlanda 791
HK - Hong Kong 767
VN - Vietnam 753
DE - Germania 521
FR - Francia 425
KR - Corea 398
FI - Finlandia 335
ZA - Sudafrica 307
SE - Svezia 301
IN - India 238
UA - Ucraina 235
BD - Bangladesh 197
NL - Olanda 176
CA - Canada 115
ES - Italia 82
AR - Argentina 77
IQ - Iraq 76
MX - Messico 76
PL - Polonia 71
TR - Turchia 47
CI - Costa d'Avorio 45
ID - Indonesia 43
JP - Giappone 42
AT - Austria 40
KE - Kenya 37
IR - Iran 33
CZ - Repubblica Ceca 30
EC - Ecuador 30
NG - Nigeria 29
SA - Arabia Saudita 29
UZ - Uzbekistan 29
CO - Colombia 27
PK - Pakistan 26
MY - Malesia 25
EG - Egitto 24
VE - Venezuela 24
AE - Emirati Arabi Uniti 23
JO - Giordania 23
CH - Svizzera 22
BE - Belgio 21
LT - Lituania 18
PY - Paraguay 18
AU - Australia 16
MA - Marocco 16
PH - Filippine 16
CL - Cile 15
PT - Portogallo 13
PE - Perù 12
AL - Albania 11
RO - Romania 11
BG - Bulgaria 10
IL - Israele 10
AZ - Azerbaigian 9
CR - Costa Rica 8
EE - Estonia 8
GT - Guatemala 8
LV - Lettonia 8
TH - Thailandia 8
BH - Bahrain 7
DK - Danimarca 7
DO - Repubblica Dominicana 7
EU - Europa 7
NP - Nepal 7
UY - Uruguay 7
BO - Bolivia 6
DZ - Algeria 6
ET - Etiopia 6
GE - Georgia 6
GR - Grecia 6
HR - Croazia 6
HU - Ungheria 6
JM - Giamaica 6
KZ - Kazakistan 6
OM - Oman 6
TN - Tunisia 6
TW - Taiwan 6
AO - Angola 5
CY - Cipro 5
LB - Libano 5
PA - Panama 5
PS - Palestinian Territory 5
SN - Senegal 5
BY - Bielorussia 4
KG - Kirghizistan 4
LK - Sri Lanka 4
MK - Macedonia 4
SV - El Salvador 4
AM - Armenia 3
HN - Honduras 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
BN - Brunei Darussalam 2
CG - Congo 2
Totale 27.091
Salva come PNG Salva come JPEG
Città #
Dallas 3.245
Singapore 1.125
Dublin 776
Hong Kong 737
Southend 700
Moscow 697
Ashburn 658
Hefei 551
San Jose 537
Santa Clara 474
Fairfield 438
Milan 428
Chandler 394
Seoul 393
Siena 301
Johannesburg 285
Beijing 281
Los Angeles 272
Ho Chi Minh City 249
Munich 247
Woodbridge 241
Helsinki 229
Houston 212
Seattle 199
Wilmington 172
Council Bluffs 171
New York 171
Jacksonville 170
Rome 161
Florence 160
Lauterbourg 160
Hanoi 159
Cambridge 158
The Dalles 144
Ann Arbor 129
Princeton 110
São Paulo 98
Bengaluru 86
Buffalo 86
Chicago 79
Nuremberg 65
Orem 64
Nanjing 54
Frankfurt am Main 51
Boardman 48
Brescia 48
Warsaw 46
Abidjan 45
London 45
Turku 44
Redondo Beach 43
Shanghai 41
Menlo Park 40
Dong Ket 39
Montreal 39
Chennai 36
Rio de Janeiro 36
Tokyo 36
San Diego 35
Düsseldorf 34
Lappeenranta 34
Toronto 34
Brooklyn 31
Málaga 31
Denver 30
Haiphong 30
Naples 30
Baghdad 29
Da Nang 29
Mexico City 28
Tashkent 27
Abuja 26
Atlanta 26
Portsmouth 26
Stockholm 26
Bologna 25
Paris 25
Columbus 22
Amman 21
Brasília 21
Brussels 21
Phoenix 21
Shenyang 21
Amsterdam 20
Vienna 20
Fremont 19
Nanchang 19
Guangzhou 18
Piscataway 18
San Francisco 18
Washington 18
Curitiba 17
Mumbai 17
Poplar 17
Boston 16
Cairo 16
Ribeirão Preto 16
Salt Lake City 16
San Mateo 16
Brno 15
Totale 17.682
Salva come PNG Salva come JPEG
Nome #
Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study 629
A first update on mapping the human genetic architecture of COVID-19 580
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 577
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 509
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 503
Genetic mechanisms of critical illness in COVID-19 425
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 416
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients 369
An explainable model of host genetic interactions linked to COVID-19 severity 368
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 359
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 350
Pathogen-sugar interactions revealed by universal saturation transfer analysis 349
null 320
Peripheral biomarkers' panel for severe COVID-19 patients 318
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 314
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 310
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 301
Programma di vaccinazione antiMpox e screening infettivologico: opportunità di prevenzione in differenti categorie a rischio 300
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 295
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 285
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 276
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 273
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 268
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 255
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 253
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 244
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 244
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 237
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 232
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 217
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 213
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 211
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 208
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 205
WES profiling of COVID-19 204
Whole-genome sequencing reveals host factors underlying critical COVID-19 201
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 200
Clinical and molecular characterization of COVID-19 hospitalized patients 194
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 191
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 190
Colonizzazione da batteri multiresistenti nel trapianto di polmone ed eventi infettivi: studio pilota osservazionale-retrospettivo 188
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses 187
THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY 187
Epidemiological and clinical study of viral respiratory tract infections in children from Italy 183
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 183
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound? 182
Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study 181
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 181
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 181
Staphylococcus aureus: studio clinico e microbiologico 180
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 179
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 179
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 178
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 177
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 176
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 176
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 173
B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response 172
Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: epidemiology, clinical features and outcomes in the era of antimicrobial resistance 171
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine In HIV-Infected Adults 171
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 171
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 170
Prevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV 170
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 168
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 167
Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features 164
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in virological outcomes over time 164
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 163
Durability and liver safety of INSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort 160
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 157
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 156
Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability 156
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 155
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 155
Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination? 153
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 153
Retrospective study of tuberculosis in the Province of Siena [Studio retrospettivo sui ricoveri per tubercolosi nella provincia di Siena] 152
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 151
Incidenza e fattori di rischio per colonizzazione ed infezione respiratoria batterica a 30 giorni in pazienti trapiantati di polmone 150
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 146
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 145
Trattamento efficace di osteomielite sternale con raccolta purulenta da Klebsiella pneumoniae multiresistente in recente trapianto di polmone 145
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 144
Vaccinazione anti SARSCov2 in una coorte di pazienti sottoposti a trapianto di cuore o di polmone: risposta umorale a dosi booster 144
High prevalence of Hepatic Steatosis in a cohort of People Living With HIV: exploring the role of metabolic and HIV-related factors 144
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants 144
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients. 141
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant 139
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 137
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 137
Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing 137
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 136
Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patient 134
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 133
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 133
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 131
A challenging case of SARS-CoV-2- AIDS and Nocardiosis coinfection from the SMatteo COvid19 REgistry (SMACORE) 130
Successivi booster vaccinali contro SARS-CoV-2: risposta umorale in pazienti sottoposti a trapianto di cuore o di polmone 128
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 126
Prevalence and correlates of Hepatic Steatosis and Metabolic-associated Fatty Liver Disease in a cohort of People Living With HIV 126
Totale 21.893
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.254
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.254
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021112 0 0 0 0 0 0 0 0 0 0 0 112
2021/20221.118 107 100 43 59 67 54 56 59 87 86 151 249
2022/20231.669 101 153 173 201 135 309 115 158 142 59 74 49
2023/20241.504 72 45 167 93 72 344 436 67 15 44 56 93
2024/20256.115 171 175 388 238 895 367 564 364 450 306 536 1.661
2025/202614.538 1.015 2.289 2.618 1.781 2.228 508 1.580 543 566 781 601 28
Totale 27.930